Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Access Program of ruxolitinib in COVID-19 associated ARDS

Next Previous
X
Search
Trial Profile

An Expanded Access Program of ruxolitinib in COVID-19 associated ARDS

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 30 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Expanded access; Therapeutic Use

    • Most Recent Events

    • 30 Mar 2021 New trial record
    • 18 Mar 2021 According to an Incyte Corporation media release, the company is in discussion with US FDA to make ruxolitinib available to eligible patients in the United States at no cost via an Expanded Access Program (EAP).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top